Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00371709
Registration number
NCT00371709
Ethics application status
Date submitted
31/08/2006
Date registered
4/09/2006
Date last updated
2/02/2012
Titles & IDs
Public title
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
Query!
Scientific title
TAXUS ATLAS: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions
Query!
Secondary ID [1]
0
0
TAXUS ATLAS
Query!
Secondary ID [2]
0
0
S2013
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - TAXUS Liberté-SR
Treatment: Devices - TAXUS™ Express
Experimental: Arm 1 -
Other: Arm 2 - Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
Treatment: Devices: TAXUS Liberté-SR
Paclitaxel-Eluting Coronary Stent System
Treatment: Devices: TAXUS™ Express
Paclitaxel-Eluting Coronary Stent System
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
9-Month Target Vessel Revascularization (TVR)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
9 Months
Query!
Secondary outcome [1]
0
0
Clinical procedural and technical success
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
5 Years
Query!
Secondary outcome [2]
0
0
Utilization parameters (equipment utilization; catheters, guidewires and balloons, procedure time, fluoroscopic time and amount of contrast used)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
9 Months
Query!
Secondary outcome [3]
0
0
MACE rates at discharge, 1, 4 and 9-months and 1, 2, 3, 4, and 5 years post-index procedure.
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
5 Years
Query!
Secondary outcome [4]
0
0
Stent thrombosis rate
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
5 Years
Query!
Secondary outcome [5]
0
0
Target Vessel Failure (TVF)
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
5 Years
Query!
Secondary outcome [6]
0
0
QCA parameters (binary restenosis rate, MLD and late loss)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
9 Months
Query!
Secondary outcome [7]
0
0
IVUS parameters (percent net volume obstruction, incomplete apposition, stent and area volumes, neointimal area volume) for patients in the IVUS subset
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
9 Months
Query!
Eligibility
Key inclusion criteria
General
1. Patient is =18 years old.
2. Eligible for percutaneous coronary intervention (PCI)
3. Documented stable angina pectoris or unstable angina pectoris with documented ischemia
or documented silent ischemia
4. Left ventricular ejection fraction (LVEF) of >/=25%
5. Acceptable candidate for coronary artery bypass grafting (CABG)
6. Patient or legal guardian understands the study requirements and the treatment
procedures and provides written Informed Consent before any study-specific tests or
procedures are performed
7. Willing to comply with all specified follow-up evaluations
Angiographic
1. Only one lesion (target lesion) may be treated with the study stent. However, one
additional lesion in a non-target vessel may be treated during the index procedure
with a commercially available bare metal stent, heparin-coated stent or TAXUS Express
stent.
2. Target lesion enrolled for treatment may be composed of multiple lesions (not more
than 10mm between diseased segments)but must be completely covered by one study stent.
3. Target lesion located within a single native coronary artery
4. Cumulative target lesion length is =10 mm and =28 mm (visual estimate)
5. RVD of =2.5 mm to =4.0 mm (visual estimate)
6. Target lesion diameter stenosis =50% (visual estimate)
7. Target lesion is de novo (i.e., a coronary lesion not previously treated)
General
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Known hypersensitivity to paclitaxel
2. Any previous, concurrent or planned treatment with a non-study anti-restenotic
drug-coated or drug-eluting coronary stent.
3. Previous or planned use of both the study stent and a non-study stent (i.e.,
commercial stent) in the treatment of the target vessel
4. Previous or planned treatment with intravascular brachytherapy in the target vessel
5. Planned CABG =9-months post-index procedure
6. MI within 72 hours prior to the index procedure and or creatine kinase(CK) >2x the
local laboratory's ULN unless CK-MB is <2x ULN.
7. Cerebrovascular Accident (CVA) within the past 6 months
8. Cardiogenic Shock
9. Acute or chronic renal dysfunction
10. Contraindication to ASA, or to both clopidogrel and ticlopidine
11. Leukopenia
12. Thrombocytopenia or thrombocytosis
13. Active peptic ulcer or active gastrointestinal (GI) bleeding
14. Known allergy to stainless steel
15. Any prior true anaphylactic reaction to contrast agents
16. Patient is currently, or has been treated with paclitaxel or other chemotherapeutic
agents within 12-months of the index procedure
17. Anticipated treatment with paclitaxel or oral rapamycin during any period in the
9-months after the index procedure
18. Male or female with known intention to procreate within 3 months after the index
procedure
19. Female of childbearing potential with a positive pregnancy test within 7 days before
the index procedure, or lactating, or intends to become pregnant during the study.
20. Life expectancy of less than 24-months due to other medical condition
21. Co-morbid condition(s) that could limit the patient's ability to participate in the
study, compliance with follow-up requirements or impact the scientific integrity of
the study
22. Currently participating in another investigational drug or device study that has not
completed the primary endpoint or that clinically interferes with the endpoints of
this study.
Angiographic
1. Left main coronary artery disease (stenosis >50%) whether protected or unprotected
2. Target lesion is ostial in location (within 3.0 mm of vessel origin)
3. Target lesion and/or target vessel proximal to the target lesion is moderately or
severely calcified by visual estimate.
4. Target lesion and/or target vessel proximal to the target lesion is tortuous.
5. Target lesion is located within or distal to a >60 degree bend in the vessel
6. Target lesion involves a bifurcation with a side branch vessel >2.0 mm in diameter.
7. Target lesion is totally occluded (TIMI flow </= 1), either at baseline or predilation
8. Angiographic presence of probable or definite thrombus
9. Pre-treatment of the target vessel is not allowed with any device
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
871
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC
Query!
Recruitment hospital [1]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [3]
0
0
Cardiovascular Research Center Monash Medical Centre - Clayton
Query!
Recruitment hospital [4]
0
0
Epworth Hospital - Richmond
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3121 - Richmond
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Delaware
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maine
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Mississippi
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Hampshire
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oklahoma
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Washington
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Wisconsin
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Alberta
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
British Columbia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Quebec
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Kowloon
Query!
Country [32]
0
0
New Zealand
Query!
State/province [32]
0
0
Epsom
Query!
Country [33]
0
0
New Zealand
Query!
State/province [33]
0
0
Auckland
Query!
Country [34]
0
0
New Zealand
Query!
State/province [34]
0
0
Christchurch
Query!
Country [35]
0
0
New Zealand
Query!
State/province [35]
0
0
Dunedin
Query!
Country [36]
0
0
Singapore
Query!
State/province [36]
0
0
Singapore
Query!
Country [37]
0
0
Taiwan
Query!
State/province [37]
0
0
Shih Lin Taipei 111
Query!
Country [38]
0
0
Taiwan
Query!
State/province [38]
0
0
Taipei 100
Query!
Country [39]
0
0
Taiwan
Query!
State/province [39]
0
0
Taipei
Query!
Country [40]
0
0
Taiwan
Query!
State/province [40]
0
0
Taiwan
Query!
Country [41]
0
0
Taiwan
Query!
State/province [41]
0
0
Tao-Yuan
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boston Scientific Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results
from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control.
The control group is a case-matched, blended population of TAXUS Express patients from the
TAXUS IV and TAXUS V de novo clinical trials. The objective of the study is to evaluate
clinical outcomes of TAXUS Liberté-SR stent in de novo lesions and to assess the
non-inferiority of TAXUS Liberté versus TAXUS Express. The TAXUS Liberté-SR stent is
hypothesized to have comparable safety and efficacy to the TAXUS Express stent.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00371709
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Mark A Turco, MD
Query!
Address
0
0
Washington Adventist Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00371709
Download to PDF